HOME > LATEST

LATEST

BUSINESS Kyowa Kirin’s FY2025 Core Operating Profit Hits Record High as Costs Fall

February 10, 2026
BUSINESS Eisai CFO Casts Oncology Pipeline Expansion as Urgent Task

February 10, 2026
BUSINESS Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep

February 10, 2026
ORGANIZATION Pharma Group Looks to Growth Strategy under Takaichi after Election Win

February 10, 2026
BUSINESS Chugai’s Hemlibra Successor Shows Promise in PI/II Study

February 10, 2026
BUSINESS Leqembi Subcutaneous Autoinjector Gets Priority Review in China

February 10, 2026
REGULATORY LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed

February 9, 2026
COMMENTARY Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

February 9, 2026
REGULATORY MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development

February 9, 2026
BUSINESS Leqembi Global Sales Hit 61.8 Billion Yen in April-December: Eisai

February 9, 2026
BUSINESS Marubeni Rolls Out Antibiotic Xenleta in China

February 9, 2026
ORGANIZATION Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases

February 9, 2026
BUSINESS HLC, Mochida Set to Launch Japan PIII Trial of Umbilical Cord-Derived MSC

February 9, 2026
BUSINESS Japan Ethical Drug Sales Up 3.2% in December: Crecon

February 9, 2026
ORGANIZATION Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief

February 6, 2026
BUSINESS Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity

February 6, 2026
BUSINESS Ono Recalls Certain Opdivo Lots over Possible Metal Contamination

February 6, 2026
BUSINESS Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry

February 4, 2026
BUSINESS Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope

February 4, 2026
REGULATORY Japan Launches Biotechnology Working Group, Roadmap Draft Due in April

February 4, 2026

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…